← DaVita HealthCare Partners overview

DaVita HealthCare Partners vs BrightSpring Health Services, Inc. Common Stock: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

DaVita HealthCare Partners Inc (DVA)

Q3 2026
▲2▼2

DaVita's strong Q2 beat overshadowed by soft guidance and falling revenue per treatment

  • Integrated Kidney Care expansion drives growth DaVita is expanding its Integrated Kidney Care program beyond hospitals, with 62,600 patients in risk-based arrangements representing $5.4 billion in annual medical spend. This growing value-based care platform boosts demand and could improve margins through performance payments.

    This is a new strategic growth driver that supports future earnings and offsets reimbursement pressure.

  • Raised 2026 guidance and share buybacks DaVita raised full-year 2026 guidance to adjusted operating income of $2.15-$2.25 billion and EPS of $14.10-$15.20, and repurchased 5 million shares through early May. This signals confidence and returns cash to shareholders, supporting the stock price.

    Guidance raise and buybacks are direct positive catalysts for the stock.

  • Q2 revenue per treatment decline and lower cash Despite beating Q2 estimates, revenue per treatment fell $1.72 sequentially to $415.87, and cash declined to $771.8 million from $782.1 million. These operational pressures weighed on investor sentiment, contributing to a 7% share drop.

    This explains the negative price reaction despite headline beats.

  • Full-year EPS guidance midpoint below consensus DaVita reaffirmed 2026 adjusted EPS guidance of $14.10-$15.20, with a midpoint of $14.65 below the $14.88 consensus. This disappointed investors and led to a 17% stock decline, as the market expected a raise.

    This is the key reason for the sharp negative price move after earnings.

July 2026
▲2▼2

DaVita's strong Q2 beat overshadowed by soft guidance and falling revenue per treatment

  • Integrated Kidney Care expansion drives growth DaVita is expanding its Integrated Kidney Care program beyond hospitals, with 62,600 patients in risk-based arrangements representing $5.4 billion in annual medical spend. This growing value-based care platform boosts demand and could improve margins through performance payments.

    This is a new strategic growth driver that supports future earnings and offsets reimbursement pressure.

  • Raised 2026 guidance and share buybacks DaVita raised full-year 2026 guidance to adjusted operating income of $2.15-$2.25 billion and EPS of $14.10-$15.20, and repurchased 5 million shares through early May. This signals confidence and returns cash to shareholders, supporting the stock price.

    Guidance raise and buybacks are direct positive catalysts for the stock.

  • Q2 revenue per treatment decline and lower cash Despite beating Q2 estimates, revenue per treatment fell $1.72 sequentially to $415.87, and cash declined to $771.8 million from $782.1 million. These operational pressures weighed on investor sentiment, contributing to a 7% share drop.

    This explains the negative price reaction despite headline beats.

  • Full-year EPS guidance midpoint below consensus DaVita reaffirmed 2026 adjusted EPS guidance of $14.10-$15.20, with a midpoint of $14.65 below the $14.88 consensus. This disappointed investors and led to a 17% stock decline, as the market expected a raise.

    This is the key reason for the sharp negative price move after earnings.

Latest
▲2▼2

DaVita's strong Q2 beat overshadowed by soft guidance and falling revenue per treatment

  • Integrated Kidney Care expansion drives growth DaVita is expanding its Integrated Kidney Care program beyond hospitals, with 62,600 patients in risk-based arrangements representing $5.4 billion in annual medical spend. This growing value-based care platform boosts demand and could improve margins through performance payments.

    This is a new strategic growth driver that supports future earnings and offsets reimbursement pressure.

  • Raised 2026 guidance and share buybacks DaVita raised full-year 2026 guidance to adjusted operating income of $2.15-$2.25 billion and EPS of $14.10-$15.20, and repurchased 5 million shares through early May. This signals confidence and returns cash to shareholders, supporting the stock price.

    Guidance raise and buybacks are direct positive catalysts for the stock.

  • Q2 revenue per treatment decline and lower cash Despite beating Q2 estimates, revenue per treatment fell $1.72 sequentially to $415.87, and cash declined to $771.8 million from $782.1 million. These operational pressures weighed on investor sentiment, contributing to a 7% share drop.

    This explains the negative price reaction despite headline beats.

  • Full-year EPS guidance midpoint below consensus DaVita reaffirmed 2026 adjusted EPS guidance of $14.10-$15.20, with a midpoint of $14.65 below the $14.88 consensus. This disappointed investors and led to a 17% stock decline, as the market expected a raise.

    This is the key reason for the sharp negative price move after earnings.

BrightSpring Health Services, Inc. Common Stock (BTSG)

Q3 2026
▲3▼1

BrightSpring's Specialty Pharmacy Boom Drives Earnings Outlook Higher

  • Specialty Pharmacy Growth Accelerates BrightSpring's specialty pharmacy revenue jumped 30% with scripts up 31%, driven by its limited distribution drug portfolio expanding to 155 programs and 12 new launches. This high-growth business is the main engine pushing BTSG's earnings and stock higher.

    This is the core new operational driver behind the company's raised guidance and stock rally.

  • Analysts Raise 2026 Earnings Estimate Zacks lifted its 2026 EPS estimate by 16 cents to $1.82, implying 82% growth, and kept a Strong Buy rating. Higher profit expectations make the stock more attractive, pushing the price up.

    This is a new analyst action that directly reflects improving fundamentals and influences investor sentiment.

  • IRA Pricing Pressure Persists BrightSpring expects the Inflation Reduction Act to cut Home and Community Pharmacy revenue by about $200 million in 2026 and Specialty and Infusion by $175 million, though EBITDA impact is minimal. This regulatory headwind caps revenue growth and weighs on sentiment.

    This is a new regulatory update that quantifies ongoing revenue pressure, a real counterweight to the growth story.

  • Strong Q2 Results and Raised Guidance BrightSpring reported 23% revenue growth to $3.87 billion, adjusted EBITDA up 44%, and raised full-year revenue and EBITDA guidance. The strong quarter and improved outlook are the foundation for the stock's 59% year-to-date gain.

    This is the key fundamental event that set the stage for the period's positive momentum.

August 2026
▲3▼1

BrightSpring's Specialty Pharmacy Boom Drives Earnings Outlook Higher

  • Specialty Pharmacy Growth Accelerates BrightSpring's specialty pharmacy revenue jumped 30% with scripts up 31%, driven by its limited distribution drug portfolio expanding to 155 programs and 12 new launches. This high-growth business is the main engine pushing BTSG's earnings and stock higher.

    This is the core new operational driver behind the company's raised guidance and stock rally.

  • Analysts Raise 2026 Earnings Estimate Zacks lifted its 2026 EPS estimate by 16 cents to $1.82, implying 82% growth, and kept a Strong Buy rating. Higher profit expectations make the stock more attractive, pushing the price up.

    This is a new analyst action that directly reflects improving fundamentals and influences investor sentiment.

  • IRA Pricing Pressure Persists BrightSpring expects the Inflation Reduction Act to cut Home and Community Pharmacy revenue by about $200 million in 2026 and Specialty and Infusion by $175 million, though EBITDA impact is minimal. This regulatory headwind caps revenue growth and weighs on sentiment.

    This is a new regulatory update that quantifies ongoing revenue pressure, a real counterweight to the growth story.

  • Strong Q2 Results and Raised Guidance BrightSpring reported 23% revenue growth to $3.87 billion, adjusted EBITDA up 44%, and raised full-year revenue and EBITDA guidance. The strong quarter and improved outlook are the foundation for the stock's 59% year-to-date gain.

    This is the key fundamental event that set the stage for the period's positive momentum.

Latest
▲3▼1

BrightSpring's Specialty Pharmacy Boom Drives Earnings Outlook Higher

  • Specialty Pharmacy Growth Accelerates BrightSpring's specialty pharmacy revenue jumped 30% with scripts up 31%, driven by its limited distribution drug portfolio expanding to 155 programs and 12 new launches. This high-growth business is the main engine pushing BTSG's earnings and stock higher.

    This is the core new operational driver behind the company's raised guidance and stock rally.

  • Analysts Raise 2026 Earnings Estimate Zacks lifted its 2026 EPS estimate by 16 cents to $1.82, implying 82% growth, and kept a Strong Buy rating. Higher profit expectations make the stock more attractive, pushing the price up.

    This is a new analyst action that directly reflects improving fundamentals and influences investor sentiment.

  • IRA Pricing Pressure Persists BrightSpring expects the Inflation Reduction Act to cut Home and Community Pharmacy revenue by about $200 million in 2026 and Specialty and Infusion by $175 million, though EBITDA impact is minimal. This regulatory headwind caps revenue growth and weighs on sentiment.

    This is a new regulatory update that quantifies ongoing revenue pressure, a real counterweight to the growth story.

  • Strong Q2 Results and Raised Guidance BrightSpring reported 23% revenue growth to $3.87 billion, adjusted EBITDA up 44%, and raised full-year revenue and EBITDA guidance. The strong quarter and improved outlook are the foundation for the stock's 59% year-to-date gain.

    This is the key fundamental event that set the stage for the period's positive momentum.

© 2026 MarketIVWhy